Quick Facts

• Support: Used to support the maintenance of bone health.
• Indication: Administered in cases of calcium and vitamin D deficiency or insufficiency.
• Management: May assist in managing certain conditions related to low bone mass.

---

What Cal-D-Vita Treats: Main Uses and Benefits

Cal-D-Vita is a combination compound indicated for use in managing states of calcium and vitamin D deficiency or insufficiency. It is primarily administered to support the maintenance of bone health throughout the lifespan.

Calcium is a key element required for the architecture of bones and teeth, and it is a necessary component for many physiological processes. Vitamin D plays a role in facilitating the absorption of calcium in the gastrointestinal tract and helps to maintain the body's normal levels of calcium and phosphate. This combination is a component of comprehensive care plans designed to support bone mineral density. When dietary intake is insufficient to meet the body’s requirements, a healthcare professional may recommend this compound to address the inadequacy.

Adequate intake of both nutrients is considered an important factor in helping to reduce the risk associated with certain bone-related conditions, such as osteoporosis, particularly in older adults.

Who can and cannot use Cal-D-Vita?

Eligibility for Cal-D-Vita is strictly defined by regulatory documents, focusing on existing mineral status, organ function, and specific comorbidities.

Populations Excluded from Use (Contraindications)

This medicine must not be used by individuals with the following conditions, as stated in the official regulatory labeling:

Condition
Hypercalcaemia (high blood calcium) or Hypervitaminosis D (excess Vitamin D)
Conditions resulting in hypercalcaemia, such as sarcoidosis, malignancy, or primary hyperthyroidism
Severe renal impairment, nephrolithiasis (kidney stones), or severe hypercalciuria
Hypersensitivity to the active ingredients or excipients (e.g., soya or peanut allergy)

Use under Restricted Conditions

• Renal Insufficiency: Use requires caution in patients with non-severe renal insufficiency and in immobilized patients.
• Pregnancy and Lactation: Use is permitted for diagnosed deficiencies, but the total daily intake of calcium and Vitamin D from all sources must not exceed regulatory limits.

Interactions with other medicines and products — official regulatory information

Official regulatory documentation for Cal-D-Vita's components highlights potential interactions that require specific restrictions or monitoring. The documented interactions are based on pharmacodynamic additive effects, pharmacokinetic absorption interference, and chelation.

Product Category
Pharmacodynamic Interactions
Thiazide Diuretics (e.g., Chlorothiazide, Chlorthalidone)
Cardiac Glycosides (e.g., Digoxin)
Absorption/Chelation Interactions
Tetracycline and Fluoroquinolone Antibiotics
Bisphosphonates
Bile Acid Sequestrants (e.g., Cholestyramine)
Mineral Oil
Metabolic/Electrolyte Interactions
Anticonvulsants (Enzyme Inducers, e.g., Phenobarbital)
Magnesium-containing products
Other Vitamin D Compounds/Analogs

Official Interaction Statements

• Thiazide diuretics and cardiac glycosides are officially noted as increasing the risk of cardiac toxicity and hypercalcemia due to additive effects on serum calcium.
• The Calcium Carbonate component is documented to bind to and reduce the absorption of certain oral drugs, including Tetracycline antibiotics and Bisphosphonates, requiring a time separation between administrations.
• Regulatory sources state that the absorption of the fat-soluble Dihydrotachysterol component is impaired by bile acid sequestrants and mineral oil.
• The use of Dihydrotachysterol with magnesium-containing products is noted to increase the risk of hypermagnesemia in patients with renal impairment.
• Coadministration with other Vitamin D analogs is specified as increasing the risk of hypercalcemia, which necessitates careful use.

Interaction-Related Constraints

To prevent reduced drug exposure through chelation, regulatory constraints require certain oral medicines to be administered at least two to four hours separately from the calcium component. Dietary constraints also specify that calcium absorption may be significantly reduced by co-ingestion with foods high in oxalic acid (e.g., spinach) or phytic acid (e.g., bran), also requiring a time separation.

Mechanism of Action

The mechanism of Cal-D-Vita is defined by the synergistic pharmacodynamic interaction between its two components. Dihydrotachysterol (DHT), a synthetic Vitamin D analog, acts as an agonist at the nuclear Vitamin D Receptor (VDR), which is prominently expressed in intestinal cells. Upon VDR activation, the resultant gene regulation cascade upregulates the synthesis of proteins required for transcellular calcium transport (e.g., TRPV6 channels and Ca^2+- ATPase). This molecular event establishes an active pathway for mineral influx from the intestinal lumen, utilizing the elemental Ca^2+ ions supplied by the Calcium Carbonate component.

Beyond the intestine, VDR agonism influences endocrine feedback loops. In the parathyroid glands, it initiates a negative feedback signal that suppresses Parathyroid Hormone (PTH) secretion. Concurrently, it increases renal tubular reabsorption of Ca^2+ within the kidneys. DHT’s metabolic characteristic of requiring only hepatic hydroxylation allows for a relatively swift engagement with mineral homeostasis compared to mechanisms requiring renal activation. The combined modulation of influx and conservation processes directly influences the regulation of Ca^2+ concentration in the serum.

Official Administration Guidelines

Administration instructions for Cal-D-Vita are structured around the product's dosage form, frequency, and critical monitoring requirements.

Instruction Category	Official Guideline
Route of Administration	The medicine is strictly for oral use (by mouth).
Preparation Requirements	Effervescent tablets must be fully dissolved in a minimum of 200 ml of water before the resulting solution is consumed.
Standard Dosing Schedule	Dosing for adults and the elderly is typically one to two tablets daily, depending on the formulation's strength (e.g., 600 mg / 400 IU effervescent tablet) or specific regional labeling.
Timing with Other Drugs	Intake must be separated from other oral medications like levothyroxine, bisphosphonates, or quinolone/tetracycline antibiotics by a specific interval (e.g., 2 to 6 hours) to prevent absorption interference.

---

Administration Protocol and Constraints

Instructions stipulate that the recommended dosage must not be exceeded. For patients on long-term treatment, guidelines mandate regular monitoring of serum and urinary calcium levels and kidney function (serum creatinine). Monitoring is considered especially important in older adults due to potential changes in renal function. Furthermore, the product should not be used in patients with severe renal impairment, and the dose must be reduced or treatment interrupted if urinary calcium exceeds 7.5 mmol / 24 hours.

This protocol defines the standardized steps for preparation, frequency, and safe continuation of the product, particularly concerning co-administration timing and long-term biochemical surveillance.

Research evidence / Overview of studies for Cal-D-Vita

---

Evidence for use in Mild Cognitive Cognitive Impairment (MCI) and Alzheimer’s Disease (AD)

Research studies explored this compound in adults diagnosed with conditions characterized by functional limitations, specifically MCI and early-stage Alzheimer’s Disease. The existing body of evidence primarily consists of small-scale, short-term randomized controlled trials (RCTs) that examined outcomes related to systemic or functional imbalance. These studies monitored outcomes related to cognitive function and memory performance.

Findings describe patterns observed in the studies over brief follow-up periods. Some trials described patterns such as a limited number of individuals reporting modest numerical changes or stability in their cognitive scores. However, findings were mixed across different studies. This evidence contributes to understanding symptom patterns but data are still emerging and certainty remains low regarding the longer-term course of the condition.

---

Evidence for use in Chronic Obstructive Pulmonary Disease (COPD)

Studies explored this compound in conditions marked by functional limitations, focusing on adults with stable Chronic Obstructive Pulmonary Disease (COPD). The research largely comprises short-term RCTs that examined outcomes reflecting daily functioning, such as lung function test results and measures of exercise tolerance. Findings describe patterns observed in the studies related to changes in pulmonary function test results. Some studies data show patterns related to limited or stable measurements in exercise capacity. Overall, evidence is limited and evidence quality varies across studies.

---

Evidence for use in Major Depressive Disorder (MDD)

Research has explored this compound in conditions characterized by fluctuating or episodic manifestations, specifically Major Depressive Disorder (MDD). The available data are drawn from small-scale, short-duration RCTs that monitored patient-reported outcomes describing perceived discomfort. Studies report how symptoms evolved within the observed populations, describing numerical score changes. Findings were mixed, and follow-up durations were limited. Long-term effects are not fully established concerning the maintenance of symptom patterns or relapse prevention. Data for certain groups remain insufficient.

---

What is still uncertain about Cal-D-Vita

A significant amount of uncertainty remains across all indications. Evidence is limited in general, with many studies having modest sample sizes and limited follow-up durations. The clinical relevance of the measured short-term score changes in conditions marked by functional limitations is not fully established. Comparative evidence is lacking in many areas. Evidence highlights what is known — and what is still uncertain — regarding long-term impacts and use in broader populations.

Common questions about Cal-D-Vita (FAQ)

---

Q: What happens if I miss a dose?

Official regulatory information for Cal-D-Vita does not provide specific instructions for managing a single missed dose. Because specific guidance is not available in the product labeling, if a dose is missed, consulting a healthcare professional, such as a doctor or pharmacist, is important for advice on managing the next dose.

Q: What should I do if I take too much Cal-D-Vita?

If too much Cal-D-Vita is taken, there is a risk of developing hypercalcaemia (high blood calcium) or hypervitaminosis D (excess Vitamin D). The official safety documentation states that in the event of an acute or chronic overdose, the medicine must be stopped immediately. Prompt medical intervention is necessary.

Q: Is this medicine available over the counter, or do I need a prescription?

Combination products like Cal-D-Vita, which include calcium and Vitamin D, are often generally classified as over-the-counter (OTC) supplements by major regulatory bodies. However, the specific requirement for a prescription may vary based on the strength of the formulation and the regulations in your region. Checking the product label or consulting a healthcare professional is necessary to confirm its availability.

Q: Can Cal-D-Vita cause weight gain?

Weight gain is not officially listed as a documented adverse reaction in the authoritative safety information for Cal-D-Vita. The most commonly reported side effects, according to regulatory documents, are generally mild and involve the gastrointestinal system, such as constipation or nausea.

Q: What is the difference between Cal-D-Vita and other common Vitamin D supplements?

The key difference, according to official information, lies in the specific type of Vitamin D compound used. Cal-D-Vita contains Dihydrotachysterol, which is a synthetic Vitamin D analog. This compound is unique because it is efficiently activated by the liver and does not require a subsequent activation step by the kidneys, unlike commonly used Vitamin D (cholecalciferol or D3) supplements.

Storage and Disposal Requirements for Cal-D-Vita

Official regulatory documents define specific environmental controls for storing Cal-D-Vita to maintain product stability and safety.

Storage Conditions

Requirement Type	Official Statement
Temperature	Must be stored below 30 C
Protection	Keep the container tightly closed and store away from excess heat and moisture
Child Safety	Must be kept out of the sight and reach of children
Stability	The effervescent solution, once prepared, should be consumed immediately

Disposal Instructions

Regarding the handling of unused or expired product, official labeling states there are no special requirements for disposal. Any unused medicinal product or waste material should be discarded in accordance with local requirements.